Angiotensin IV-mediated enhancement of SARS-CoV-2 cell entry could increase the viral reservoir in the brain, particularly in females, potentially contributing to the higher prevalence of COVID-19–related neurological symptoms in women. The gene discussed is AGT; the disease is COVID-19.